In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 41 to 50 of 294

TitleTypeExpected publication date
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]Technology appraisal guidanceTBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]Technology appraisal guidance
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]Technology appraisal guidanceTBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]Technology appraisal guidance
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Technology appraisal guidance
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All